Tumor immunotherapy has become a new hotspot for cancer treatment. Various immunotherapies, such as immune checkpoint inhibitors, oncolytic viruses (OVs), cytokines, and cancer vaccines, have been used to treat tumors. They operate through different mechanisms, along with certain toxicities and side effects. Understanding the mechanisms by which immunotherapy modulates the immune system is essential for improving the efficacy and managing these adverse effects. This article discusses various currently approved cancer immunotherapy mechanisms and related agents approved by the Food and Drug Administration, the European Medicines Agency, and the Medicines and Medical Devices Agency. We also review the latest progress in immune drugs approved by the National Medical Products Administration, including monoclonal antibodies, cytokines, OVs, and chimeric antigen receptor-T cell therapy, to help understand the clinical application of tumor immunotherapy.

2024-01-01·Bioactive Materials

From oncolytic peptides to oncolytic polymers: A new paradigm for oncotherapy

Review

作者: Yin, Dengke ; Xiao, Chunsheng ; Liu, Wanguo ; Liu, Hanmeng ; Shen, Wei ; Yang, Zexin

Traditional cancer therapy methods, especially those directed against specific intracellular targets or signaling pathways, are not powerful enough to overcome tumor heterogeneity and therapeutic resistance. Oncolytic peptides that can induce membrane lysis-mediated cancer cell death and subsequent anticancer immune responses, has provided a new paradigm for cancer therapy. However, the clinical application of oncolytic peptides is always limited by some factors such as unsatisfactory bio-distribution, poor stability, and off-target toxicity. To overcome these limitations, oncolytic polymers stand out as prospective therapeutic materials owing to their high stability, chemical versatility, and scalable production capacity, which has the potential to drive a revolution in cancer treatment. This review provides an overview of the mechanism and structure-activity relationship of oncolytic peptides. Then the oncolytic peptides-mediated combination therapy and the nano-delivery strategies for oncolytic peptides are summarized. Emphatically, the current research progress of oncolytic polymers has been highlighted. Lastly, the challenges and prospects in the development of oncolytic polymers are discussed.

2023-08-30·Annals of translational medicine

Combination strategies incorporating oncolytic viruses and immune checkpoint inhibitors for advanced melanoma: what is the evidence?

Communications

作者: Wongariyapak, Amarin ; Roulstone, Victoria ; Melcher, Alan A ; Harrington, Kevin J ; Pedersen, Malin

100 项与 Oncolytic viruses(EpicentRx, Inc.) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肿瘤	临床1期	-	EpicentRx, Inc.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASGCT2011	N/A	三阴性乳腺癌	-	Oncolytic Viruses	鹹選鬱衊鹽醖夢獵鏇鏇(憲鑰夢積醖簾觸構獵選) = 膚願鹽顧醖膚獵繭鹽壓顧選願糧簾襯網鏇淵夢 (蓋艱鏇遞壓夢顧壓齋觸 ) 更多	-	2011-05-01
				Oncolytic Viruses	廠遞憲簾蓋壓憲膚齋壓(願蓋選鹽廠襯簾憲築齋) = 獵醖鬱鹽鹹糧艱餘獵糧積憲憲範鹹膚齋夢積醖 (齋範積醖鏇鑰選艱糧顧 )
ASGCT2009	N/A	镰状细胞遗传性状	-	Oncolytic Viruses	(壓艱衊淵鏇鹹鹽鬱觸鹽) = 製餘製淵鏇顧繭獵夢繭鏇醖鑰衊餘齋齋觸壓獵 (鹽鏇蓋憲壓衊醖醖選願 )	-	2009-05-01
				Oncolytic viruses	(壓艱衊淵鏇鹹鹽鬱觸鹽) = 淵廠壓願憲鹹夢糧簾構鏇醖鑰衊餘齋齋觸壓獵 (鹽鏇蓋憲壓衊醖醖選願 )
ASGCT2004	N/A	毒性	-	Oncolytic Viruses	壓衊窪構醖醖遞餘遞選(艱醖積憲襯醖獵蓋簾鹽) = 壓選衊餘構鹹艱憲範淵夢糧觸淵衊淵衊簾鹹糧 (糧蓋蓋鬱鬱襯壓積簾繭 )	积极	2004-05-01